Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Shareholder Information

Other Exchanges and Trading Platforms
Shares in Issue
Significant Shareholdings
Director Shareholdings
Shares Not in Public Hands
Restrictions in Transfer of AIM Securities
UK City Code on Takeovers and Mergers

see Shareholder Information

Advisors

see Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

October 1, 2020

LungLife AI, with Collaborators from Mount Sinai and MD Anderson, to Present Clinical Data on Liquid Biopsy Test for Early Lung Cancer Detection

Thousand Oaks, CA – October 1, 2020 – LungLife AI, a leader in liquid biopsy technology for cancer diagnosis and management, announced today that clinical data from a research collaboration in early lung cancer detection will be presented at the International Association for the Study of Lung Cancer (IASLC) Hot Topic Meeting taking place on October 2nd […]

• Read More

December 23, 2019

LungLife AI Receives CLIA certification for its Cancer Diagnostic Laboratory

LungLife AI the developer of an Artificial Intelligence (AI) enabled non-invasive liquid biopsy test for the early detection of lung cancer, announced today that the Company has received certification from the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the “deemed status” provision of the US Department of Health and Human Services (HHS) Center for […]

• Read More

« Previous 1 … 22 23 24

More News